Recent Updates
Recently added Catalysts

ACP-044 Dose A

Phase 2

Acute Postoperative Pain | Small molecule | Pain |ACADIA Pharmaceuticals Inc.|Last Updated: May 3, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment239
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04855240Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following BunionectomyPHASE2 COMPLETED 239Mar 29, 2021Mar 14, 2022May 3, 20234 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) of Pain Intensity Scores From Time 0 (When First Dose on Day 1 is Administered) Through 24 Hours
0-24 hours

Pain (efficacy) assessments were recorded hourly (±15 minutes) for a 12-hour interval on Day 1 beginning immediately prior to the fifth dose (time 0) administered in the study. Pain assessments were continued every 3 hours during the subsequent 12 hour interval, and then every 6 hours thereafter until 72 hours, then once daily in the morning until the follow-up clinical visit. Pain assessments were also obtained immediately prior to the administration of rescue medication. A 0 to 10 Numeric Rating Scale of Pain Intensity (NRS) was used to assess the subject's pain. Subjects were asked: "Please describe your foot pain at the present time from 0 to 10 where "0" means "no pain at all" and "10" means "the worst pain imaginable." The area under the curve is generated using the following timepoints beginning immediately prior to the fifth dose (time 0): 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, 21, and 24 hours.

Secondary Endpoints
Time to First Rescue Medication Use After Time 0 (When First Dose on Day 1 is Administered)
0-72 hours
Proportion of Subjects Who Were Opioid Free Through 24 Hours
0-24 hours
Proportion of Subjects Who Were Opioid Free Through 48 Hours
0-48 hours
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Drug - ACP-044 Dose AEXPERIMENTALACP-044 Dose A
Drug - ACP-044 Dose BEXPERIMENTALACP-044 Dose B
PlaceboPLACEBO_COMPARATORPlacebo
Interventions
NameTypeDescription
ACP-044 Dose ADRUGOral dose of ACP-044 Dose A
ACP-044 Dose BDRUGOral dose of ACP-044 Dose B
PlaceboDRUGOral dose of placebo
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: * Male or female ≥18 and \<60 years of age at the time of Screening * Has a body mass index (BMI) \<40 kg/m2 * Able to understand and provide signed informed consent * Able to complete subject-reported outcome measures * Is in need of a primary unilateral, first metatarsal bunio...

Countries:United States
Unlock Eligibility Criteria